Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Mesothelioma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 12Nivolumab 6Cyclophosphamide 6fludarabine 5Ipilimumab 4amatuximab 3Cisplatin 3tislelizumab 2spartalizumab 2fludarabine phosphate 2budigalimab 2belinostat 2Plicamycin 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Cytoreduction Surgical Procedures 2venetoclax 1tocilizumab 1talazoparib 1sotorasib 1rovalpituzumab tesirine 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1irinotecan sucrosofate 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Pentostatin × Gastrointestinal × Clear all
NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
55 enrolled 22 charts
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡